Abstract
Modified adenoviruses represent a new approach to treatment of gastrointestinal cancer. However, their uptake by cells in many cases requires the major receptor for adenoviruses, the coxsackievirus and adenovirus receptor (CAR). Thus, lack of CAR expression is a potential cause of intrinsic resistance of tumor cells to this type of treatment. To evaluate this, we studied the localization of CAR protein in normal and malignant gastrointestinal tissues. In normal tissues, CAR was concentrated at sites of cell–cell interaction, in particular at the apico-lateral cellular surface. Expression was particularly strong around bile and pancreatic ducts, which is in agreement with CAR's physiological function as a tight-junction protein. In GI malignancies (esophageal, pancreatic, colorectal and liver cancer), expression of the receptor varied substantially. Loss of CAR expression at cell–cell junction was evident in many samples. A significant correlation between CAR expression and histological grade was found, with moderately to poorly differentiated tumors most frequently demonstrating loss or reduction of CAR expression. These data indicate that CAR expression is frequently altered in gastrointestinal malignancy, potentially reducing the efficacy of adenovirus-based therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Parkin DM, Bray FI, Devesa SS . Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (Suppl 8): S4–S66.
Chu RL, Post DE, Khuri FR, Van Meir EG . Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299–5312.
Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070–6079.
Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320–1323.
Cohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, Bergelson JM . The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci USA 2001; 98: 15191–15196.
Sachs MD, Rauen KA, Ramamurthy M, Dodson JL, De Marzo AM, Putzi MJ et al. Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology 2002; 60: 531–536.
Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res 2002; 62: 3812–3818.
Anders M, Hansen R, Ding RX, Rauen KA, Bissell MJ, Korn WM . Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor. Proc Natl Acad Sci USA 2003; 100: 1943–1948.
Au T, Thorne S, Korn WM, Sze D, Kirn D, Reid T . Minimal hepatic toxicity following infusion of adenoviral vector: spatial restriction of CAR receptor in normal liver. Cancer Gene Ther 2006 (in press).
Senzer N, Hanna N, Chung T, Nemunaitis J, Rosemurgy A, Javle M et al. Updated response and survival data for TNFerade combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC). Paper presented at: Proc Am Soc Clin Oncology, 2005, Orlando.
Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22: 1389–1397.
Venook AP, Warren RS . Therapeutic approaches to metastasis confined to the liver. Curr Oncol Rep 2001; 3: 109–115.
Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Lee M, Kirn DH . A phase I/II trial of intratumoral endoscopic ultrasound (EUS) injection of Onyx-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Paper presented at: Proc Am Assoc Clin Oncol, 2000.
Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Therapy 2001; 8: 308–315.
Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Therapy 2001; 8: 1618–1626.
Warren RS, Kirn DH . Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond. Surg Oncol Clin N Am 2002; 11: 571–588, vi.
Reid TR, Freeman S, Post L, McCormick F, Sze DY . Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 2005; 12: 673–681.
Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT . Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001; 61: 813–817.
Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325–330.
Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT . The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000; 60: 5031–5036.
Tallone T, Malin S, Samuelsson A, Wilbertz J, Miyahara M, Okamoto K et al. A mouse model for adenovirus gene delivery. Proc Natl Acad Sci USA 2001; 98: 7910–7915.
Pedersen KB, Nesland JM, Fodstad O, Maelandsmo GM . Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies. Br J Cancer 2002; 87: 1281–1286.
Kanazawa T, Watanabe T, Kazama S, Tada T, Koketsu S, Nagawa H . Poorly differentiated adenocarcinoma and mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of E-cadherin expression due to methylation of promoter region. Int J Cancer 2002; 102: 225–229.
Pong RC, Lai YJ, Chen H, Okegawa T, Frenkel E, Sagalowsky A et al. Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. Cancer Res 2003; 63: 8680–8686.
Kitazono M, Goldsmith ME, Aikou T, Bates S, Fojo T . Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res 2001; 61: 6328–6330.
Bruning A, Runnebaum IB . The coxsackie adenovirus receptor inhibits cancer cell migration. Exp Cell Res 2004; 298: 624–631.
Anders M, Christian C, McMahon M, McCormick F, Korn WM . Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res 2003; 63: 2088–2095.
Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, Oft M et al. TGF-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of CAR in conjunction with reversal of epithelial–mesenchymal-transition. Cancer Res 2006; 66: 1648–1657.
Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 95: 652–660.
Smith TA, Idamakanti N, Marshall-Neff J, Rollence ML, Wright P, Kaloss M et al. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther 2003; 14: 1595–1604.
Acknowledgements
We thank Dr Montgomery Bissell and Tina Korn for critical reading of the manuscript. This work was supported by NIH/National Cancer Institute Grants: P30 CA82103, P30 DK26743, P50CA89520, 5R25GM59298-02 (graduate fellowship to MM), and the UCSF Hellman Family Award.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Korn, W., Macal, M., Christian, C. et al. Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation. Cancer Gene Ther 13, 792–797 (2006). https://doi.org/10.1038/sj.cgt.7700947
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700947
Keywords
This article is cited by
-
Oncolytic viruses: adenoviruses
Virus Genes (2017)
-
JAM-related proteins in mucosal homeostasis and inflammation
Seminars in Immunopathology (2014)
-
Presence of the Coxsackievirus and Adenovirus Receptor (CAR) in human neoplasms: a multitumour array analysis
British Journal of Cancer (2013)
-
CAR regulates epithelial cell junction stability through control of E-cadherin trafficking
Scientific Reports (2013)
-
A simple detection system for adenovirus receptor expression using a telomerase-specific replication-competent adenovirus
Gene Therapy (2013)